
    
      This study is testing vemurafenib and hydroxychloroquine (HCQ) in the treatment of metastatic
      BRAF V600E+ melanoma. Patients will be getting a known active treatment for their disease in
      combination with HCQ which may help overcome resistance so that responses to vemurafenib are
      more durable.
    
  